Connor, Clark & Lunn Investment Management (CC&L)
INDV icon

Connor, Clark & Lunn Investment Management (CC&L)’s Indivior Pharmaceuticals INDV Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$470K Buy
+11,463
New +$416K ﹤0.01% 1400

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s INDV Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2026: 11,463 shares worth $470K. The stake represents ﹤0.01% of the portfolio and ranks #1400 among its holdings.

336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 11,463 shares of Indivior Pharmaceuticals worth $470K as of Q2 2026.
  • Indivior Pharmaceuticals was a new Connor, Clark & Lunn Investment Management (CC&L) position in Q2 2026.
  • Indivior Pharmaceuticals made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1400 holding.
  • 336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.